Cardiology Studies

INDICATION

AGE CRITERIA

DESCRIPTION

Heart Failure + HyperKalemia

≥ 18 yrs. old

A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium CyclosilicatE in Heart Failure (PRIORITIZE HF)

Heart Failure

≥ 18 yrs. old

Home-Based Fluid Status Monitoring in Heart Failure Patients Recently Hospitalized for Acute Heart Failure